^
    3d
    7MeERT Enhances Antibody-Drug Conjugate Efficacy in Glioblastoma by Inducing AMPK-p38MAPK-Mediated Non-Canonical Endocytosis of EGFRvIII. (PubMed, Anticancer Agents Med Chem)
    7MeERT enhances EGFRvIII-targeting ADC efficacy in glioblastoma by inducing metabolic stress and triggering AMPK-p38MAPK-mediated non-canonical endocytosis. This strategy may improve ADC delivery in tumors with impaired receptor internalization.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    depatuxizumab mafodotin (ABT-414)
    3d
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin)
    3d
    Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, HuiKai Li
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4d
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) (clinicaltrials.gov)
    P3, N=446, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • albumin-bound paclitaxel • izalontamab brengitecan (BL-B01D1)
    7d
    PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC (clinicaltrials.gov)
    P1, N=396, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    Ameile (aumolertinib)
    8d
    A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) (clinicaltrials.gov)
    P3, N=418, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)
    8d
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=403 --> 167
    Enrollment closed • Enrollment change • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    8d
    A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • izalontamab brengitecan (BL-B01D1)
    8d
    A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Lynparza (olaparib) • abiraterone acetate • izalontamab brengitecan (BL-B01D1)
    9d
    BL-B01D1-210: A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=74, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=46 --> 74
    Enrollment change
    |
    Avastin (bevacizumab) • Lenvima (lenvatinib) • izalontamab brengitecan (BL-B01D1) • Anyouping (finotonlimab)
    11d
    BLOOM-ON: Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=102, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    11d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010